- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Engineered enzyme against antibiotic-resistant anthrax - Video
|
Overview
Antibiotic-resistant strains of the bacteria are of growing concern, and researchers are preparing to fight back. Now, a team reporting in ACS Infectious Diseases has taken a step toward the development of a therapeutic that can treat the infection in mice without antibiotics.
One type of B. anthracis, called the Ames strain, is particularly virulent because it can wrap itself in a protective capsule of poly-D-glutamic acid that acts like a cloak of invisibility, helping the bacteria evade the human immune system.
A B. anthracis enzyme called CapD anchors the capsule material to the bacteria, but previous studies have reported that the enzyme can be engineered to degrade the capsule instead, making the bacteria susceptible to the immune system.
Studies have also shown that providing mice with the engineered CapD can help treat an Ames- strain anthrax infection without the use of antibiotics. In addition, Patricia Legler and colleagues have demonstrated that adding polyethylene glycol (PEG) to this version of CapD can help the enzyme stick around longer, increasing mouse survival. In this study, the team wanted to optimize the treatment even further.
To improve the re-engineered enzyme's lifetime in the body and deliver a bigger punch, the researchers added PEG and fused the CapD protein with part of a mouse antibody. This resulted in two CapD enzymes bound together, which would essentially double its capsule- binding power.
The researchers created several versions of the enzyme and subjected them to many rounds of optimization, deleting and inserting different segments until they achieved a sequence that both held its 3D shape and performed as expected in a range of pH values. When tested in a mouse model, this construct lasted longer than the previous version without the fused antibody, though it had reduced activity.
Reference:
Patricia M. Legler et al, ACS Infectious Diseases, DOI: 10.1021/acsinfecdis.2c00227
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed
Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751